PRME — Prime Medicine, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1894562 ·
Last close
$2.90
Market Cap
$525.99M
52W High
$6.94
52W Low
$2.67
ADV30
3,026,897
Next earnings
2026-11-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,154,000 | — | -43,285,000 | -42,109,000 | 249,040,000 | 47,451,000 | 209,231,000 |
| Mar 2026 | 856,000 | — | -50,654,000 | -49,122,000 | 294,730,000 | 64,106,000 | 218,030,000 |
| Dec 2025 | 838,000 | — | -48,608,000 | -46,079,000 | 342,733,000 | 63,032,000 | 221,865,000 |
| Sep 2025 | 1,225,000 | — | -53,973,000 | -50,582,000 | 385,012,000 | 71,396,000 | 223,191,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-156,051,000
Investing CF
$3,629,000
Financing CF
$146,069,000
CapEx
$-797,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.25
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$979,585,000
Inventory
—
Receivables
$120,000
ST Investments
$71,391,000
EBIT TTM
$-196,520,000
Pretax Income TTM
$-187,892,000
Interest Exp TTM
—
Analysts
9
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,073,000
EBITDA
$-189,122,000
Free Cash Flow
$-75,780,000
Enterprise Value
$574,247,488
Total Cash
$95,071,000
Total Debt
$112,478,000
Shares Out
181,376,856
Trailing EPS
$-1.05
Book Value
$0.23
ROE
-373.3%
ROA
-46.5%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,632,000 | -208,350,000 | -201,142,000 | 342,733,000 | 221,865,000 | 120,868,000 | -162,564,000 |
| Dec 2024 | 2,983,000 | -202,467,000 | -195,882,000 | 297,508,000 | 144,359,000 | 153,149,000 | -122,865,000 |
| Dec 2023 | 0 | -191,292,000 | -198,133,000 | 193,851,000 | 60,780,000 | 133,071,000 | -165,412,000 |
| Dec 2022 | 0 | -116,544,000 | -121,821,000 | 360,314,000 | 44,044,000 | 316,270,000 | -131,827,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.88
Max Pain — expiry 2027-01-15
max pain strike: $4.00 · spot: $2.80 · call oi: 8,615 · put oi: 3,600
Expected Move to 2027-01-15:
±$1.30
(46.43%) —
implied range
$1.50 –
$4.10
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AGMB | AgomAb Therapeutics NV | $517.60M | $10.51 | — |
| AUTL | Autolus Therapeutics plc | $493.73M | $1.86 | — |
| RGNX | REGENXBIO Inc. | $488.50M | $7.40 | — |
| ALLO | Allogene Therapeutics, Inc. | $570.06M | $1.65 | — |
| ENTX | Entera Bio Ltd. | $475.27M | $2.74 | — |
News headlines (Yahoo Finance, 1h cache)
Prime Medicine stock surges on FDA IND clearance
2026-09-24 20:47 · Yahoo
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
2026-09-23 21:49 · Yahoo
Prime Medicine to Participate in Upcoming Investor Conferences
2026-09-03 12:00 · Yahoo
Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-06 12:00 · Yahoo
Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
2026-07-30 14:00 · Yahoo
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
2026-07-23 20:05 · Yahoo
Prime Medicine (PRME) Reaches Positive Resolution to Arbitration with Beam Therapeutics
2026-07-15 08:53 · Yahoo
Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle
2026-07-08 20:09 · Yahoo
PRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drug
2026-07-08 16:47 · Yahoo
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
2026-07-08 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.